Researcher
Diether Lambrechts
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
Affiliations
- Laboratory of Translational Genetics (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - VIB-KU Leuven Center for Cancer Biology (Research Center)
Responsible
From1 Jan 2017 → Today - Lambrechts Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Translational Genetics (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 2003 → 30 Sep 2005 - Department of Cellular and Molecular Medicine (Department)
Member
From1 Oct 1999 → 30 Sep 2003
Projects
1 - 10 of 72
- Liquid biopsy and HRD testing in ovarian cancerFrom4 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Decoding the penile cancer tumor microenvironment: heterogeneity of tumor-associated epithelial cell states, it's relationship with HPV, and it's role in prognosis and therapy response.From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Integration of Spatial Transcript- and Proteomics Techniques with Pan-cancer single cell RNA-sequencing data to interrogate the impact of immunotherapy on the Tumor Microenvironment (TME)From9 May 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- An Integrated Spatial Atlas of the Tumor Micro-environment of Early Non-Small Cell Lung CancerFrom16 Mar 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Abemaciclib and letrozole in ER positive rare ovarian cancerFrom1 Mar 2023 → TodayFunding: Foundations, funds and other with scientific goal
- SymBioSys: Computationally mapping genomic heterogeneity from long read sequencing dataFrom1 Oct 2022 → TodayFunding: BOF - projects
- Refining the role of dual checkpoint inhibition in advanced lung cancer: a single-cell approachFrom5 Oct 2021 → TodayFunding: FWO Strategic Basic Research Grant
- Multiomic Integration of cell-free DNA profiles to Advance Disease OutcomeFrom1 Oct 2021 → TodayFunding: FWO Strategic Basic Research (SBO)
- Connecting Single-cell Immune Profiling in Peripheral Blood with Intratumoral T Cell Expansion in Breast Cancer Upon Checkpoint ImmunotherapyFrom24 Aug 2021 → TodayFunding: FWO Strategic Basic Research Grant
- Developing personalized treatment for advanced penile cancer trough establishment of Patient-Derived Tumor Xenografts (PDTXs).From9 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
21 - 30 of 609
- Homologous Recombination Deficiency as predictive and prognostic genetic marker in ovarian cancer. Bridging the gap between ‘one-size-fits-all’ and a more personalised treatment approach.(2023)
Authors: Liselore Loverix, Toon Van Gorp, Diether Lambrechts, Ignace Vergote
- Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)(2023)
Authors: Lisa Kinget, Isaure Vanmeerbeek, Diether Lambrechts, Bram Boeckx, Maarten Albersen, Sabine Tejpar, Benoit Beuselinck, Abhishek Garg
Pages: S1026 - S1027 - The ongoing search for biomarkers of response to systemic therapy in advanced hepatocellular carcinoma.(2023)
Authors: Sarah Cappuyns, Jeroen Dekervel, Eric Van Cutsem, Chris Verslype, Diether Lambrechts
- Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features(2023)
Authors: Beppe Floris, Kristel Van Calsteren, Patrick Neven, Sileny Han, Daniela Annibali, Diether Lambrechts, Liesbeth Lenaerts, Frédéric Amant
Pages: 3729 - 3743 - A Likelihood Ratio Approach for Utilizing Case-Control Data in the Clinical Classification of Rare Sequence Variants: Application to BRCA1 and BRCA2(2023)
Authors: Diether Lambrechts
- Single-cell phenotyping to unravel the immunopathology of immune checkpoint inhibitor-related pneumonitis. Lessons learnt from the COVID-19 pandemic(2023)
Authors: Pierre Van Mol, Els Wauters, Johan Vansteenkiste, Diether Lambrechts
- Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors(2023)
Authors: Yentl Lambrechts, Sigrid Hatse, François Richard, Bram Boeckx, Beppe Floris, Christine Desmedt, Patrick Neven, Diether Lambrechts, Hans Wildiers
- A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry(2023)
Authors: Thaïs Baert, Diether Lambrechts, Ann Smeets, Hans Wildiers
- Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival(2023)
Authors: Diether Lambrechts, Ines Nevelsteen, Patrick Neven, Hans Wildiers
Pages: 16142 - 16162 - Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk(2023)
Authors: Sigrid Hatse, Diether Lambrechts, Hans Wildiers
Patents
1 - 10 of 10
- Predicting chronic allograft injury through age-related dna methylation (Inventor)
- Disease detection in liquid biopsies (Inventor)
- Retrotransposon biomarkers (Inventor)
- Detection of ovarian cancer in liquid biopsies (Inventor)
- Markers for determining tumor hypoxia (Inventor)
- Disease detection in liquid biopsies (Inventor)
- Predicting chronic allograft injury through age-related dna methylation (Inventor)
- Predicting age using dna methylation signatures (Inventor)
- Retrotransposon biomarkers (Inventor)
- Predicting chronic allograft injury through ischemia-induced dna methylation (Inventor)